跳至主要内容
临床试验/NCT06523140
NCT06523140招募中不适用

Management of Chronic Obstructive Pulmonary Disease (COPD) Patients With BoraCare® Remote Monitoring Solution Including BVS3 Early Detection Score for COPD Exacerbations

Biosency20 个研究点 分布在 1 个国家目标入组 380 人开始时间: 2024年11月20日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
Biosency
入组人数
380
试验地点
20
主要终点
Demonstrate the superiority of remote monitoring with the Bora Care solution in patients with COPD and frequent exacerbations compared to conventional follow-up.

研究概览

简要总结

The goal of this clinical trial is to demonstrate the superiority of remote monitoring with the Bora Care solution in patients with COPD and frequent exacerbations (experimental group) compared to conventional follow-up alone (control group) on the total number of hospital days per patient for respiratory deterioration over 12 months of follow-up.

The main question it aims to answer is: Does remote monitoring of COPD patients reduce the average annual length of hospitalization for exacerbations of COPD patients?

All participants will benefit a conventional clinical follow-up.

Participants in experimental group will also benefit from the Bora care remote monitoring system.

详细描述

Control group (control): conventional follow-up For the target population (frequent exacerbating COPD patients), the usual follow-up includes two consultations with the general practitioner and one consultation with the pulmonologist per year. The inclusion and follow-up visit at 12 months by a pulmonologist are consistent with the follow-up of COPD patients in current practice and the recommendations of HAS (National Authority for Health) and SPLF (French-Language Society of Pneumology).

Experimental group (conventional monitoring + remote monitoring):

The patients will be subject to conventional clinical follow-up and at the same time benefit from the Bora care remote monitoring system. The Bora care remote monitoring system includes a BoraBand wristband measuring vital signs at home, the Bora Connect platform for caregiver visualization of data and the BVS3 score for early detection of COPD exacerbations. Patients are monitored daily remotely by Case Managers (nurses trained in Bora Care solution), who, when the BVS3 > 3 alert is triggered on Bora Connect, call the patient to inform the patient about his symptoms, then alert the pulmonologist by transmitting the information from Bora Connect and the minutes of the phone call, who, according to conventional management, decides whether or not to hospitalize the patient, or to generate an unscheduled consultation in order to prescribe drug treatment, and/or to prescribe additional examinations, and/or to adapt the patient's oxygen therapy prescription.

The Case Manager re-evaluates the situation after 48 hours and 96 hours if necessary and forwards the information to the pulmonologist. The nature of the transmission of information (telephone or email) between the Case Manager and the pulmonologist in case of an alert is defined when the patient is included by the pulmonologist. If desired, remotely monitored patients will be able to access the Bora Connect interface provided for patients (restricted viewing of data).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient over 18 years of age with COPD defined according to the recommendations of the SPLF, whose level of respiratory function in a stable state is known (measured less than 12 months), recruited in pulmonology
  • Patient who has been hospitalized for COPD exacerbation in the previous 12 months
  • Informed patient who has signed consent,
  • Patient enrolled in a social security scheme (Art L1121-11 of the CSP)

排除标准

  • Presence of a comorbidity considered unstable or very severe by the investigator.
  • Patient with psychological frailties,
  • Patient already included in another interventional trial,
  • Patient who does not speak French and is unable to use the Bora Band tool and without access to a caregiver,
  • Patient protected under guardianship or unable to give free and informed consent.
  • Pregnant or nursing woman

结局指标

主要结局

Demonstrate the superiority of remote monitoring with the Bora Care solution in patients with COPD and frequent exacerbations compared to conventional follow-up.

时间窗: 1 year

Number of hospital days for respiratory deterioration per patient over 12 months.

次要结局

  • Evaluate the effect of the device on the number of hospitalizations per patient.(1 year)
  • Assess patient and caregiver satisfaction with the device. (1)(1 year)
  • Evaluate the effect of the device on the average length of stay.(1 year)
  • Assess the overall quality of life of patients at baseline and at the end of the trial. (1)(1 year)
  • Assess the overall quality of life of patients at baseline and at the end of the trial. (3)(1 year)
  • Assess the overall quality of life of patients at baseline and at the end of the trial. (2)(1 year)
  • Assess the conformity of use of the Bora Care device.(3 years)
  • Assess the impact of the device on the organisation of care. (1)(3 years)
  • Assess the impact of the device on the organisation of care. (2)(3 years)
  • Assess the impact of the device on the organisation of care. (3)(3 years)
  • Assess the impact of the device on the quality of support. (1)(3 years)
  • Assess the impact of the device on the quality of support. (3)(3 years)
  • Assess patient and caregiver satisfaction with the device. (2)(1 year)
  • Assess patient and caregiver satisfaction with the device. (3)(1 year)
  • Evaluate the performance of the warning device in the early detection of exacerbations.(3 years)
  • Identify new markers of exacerbations or other clinical events.(3 years)

研究者

发起方
Biosency
申办方类型
Industry
责任方
Sponsor

研究点 (20)

Loading locations...

相似试验

Management of COPD Patients With BoraCare® Remote... | 临床试验